Co-author Dr. Ghazaleh Eskandari-Sedighi and postdoctoral scholar in the Blurton-Jones Lab
The Blurton-Jones lab, in collaboration with several other prominent research groups in the US and Japan, recently published an article in the journal Nature describing the role of TIM-3, a newly characterized molecule implicated in sporadic AD. The lead researchers on the project, Drs. Oleg Butovsy and Vijay Kuchroo, from Brigham and Women’s Hospital and Harvard Medical School, discovered the signaling pathway through which TIM-3, an immune-checkpoint molecule (encoded by HAVCR2 gene) regulates microglia function. The Blurton-Jones Lab played a critical role in this project by providing the human microglia modeling platform needed to complement the team’s detailed studies in non-human cell models as well as a mouse model of AD. These cells were derived from induced pluripotent stem cell (iPSC) cells obtained from research participants in our Alzheimer’s Disease Research Center (ADRC). This work highlights the innovative work being conducted in the Blurton-Jones Lab and more broadly, the critical role that ADRC’s play in supporting biomedical research around the globe.
